Novartis shares rise 1.02% premarket after signing a $30 million deal with BioArctic for new treatments.

Novartis Ag rose 1.02% in premarket trading, following the announcement of a collaboration with Swedish biopharmaceutical company BioArctic. The partnership aims to develop new treatments for serious neurological diseases, with BioArctic receiving an initial payment of $30 million. This collaboration is expected to drive future growth and innovation in the treatment of neurodegenerative diseases.